Atea's oral drug bemnifosbuvir for COVID-19 gets FDA fast track status

Iryna Drozd

• The U.S. Food and Drug Administration (FDA) granted fast track designation to Atea Pharmaceuticals' (NASDAQ:AVIR) bemnifosbuvir to treat COVID-19.
• The oral antiviral drug is being evaluated in a phase 3 trial called SUNRISE-3 to treat COVID-19 in outpatients at high risk for disease progression regardless of vaccination status.
• This includes patients over 80 years of age, patients 65 years or older with at least one major risk factor, and anyone over 18 years of age who is immunocompromised, the company added.
• AVIR +1.51% to $3.25 premarket April 25